Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AORT

Artivion Inc

Nov 18 • 11:43AM ET

45.07

-0.05 -0.11 %

Healthcare • Medical Devices • USA • NYSE

Peers: MDT ABT EW SYK BSX ISRG ZBH TFX NVCR IART

| Held by: IJR VTI IWM VXF IJT SPSM IWO IHI SLYG SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.24	Insider Own	9.28%	Shs Outstand	47.38M	Perf Week	-3.82%
Market Cap	2.14B	Forward P/E	100.16	EPS next Y	0.45	Insider Trans	-5.15%	Shs Float	42.98M	Perf Month	5.77%
Enterprise Value	2.32B	PEG	-	EPS next Q	0.06	Inst Own	89.51%	Short Float	3.21%	Perf Quarter	4.77%
Income	-9.12M	P/S	5.05	EPS this Y	161.46%	Inst Trans	3.95%	Short Ratio	3.35	Perf Half Y	54.51%
Sales	422.65M	P/B	4.87	EPS next Y	128.81%	ROA	-1.10%	Short Interest	1.38M	Perf YTD	57.64%
Book/sh	9.26	P/C	29.08	EPS next 5Y	-	ROE	-2.45%	52W High	48.04 -6.18%	Perf Year	66.99%
Cash/sh	1.55	P/FCF	135.57	EPS past 3/5Y	5.41% -	ROIC	-1.31%	52W Low	21.97 105.14%	Perf 3Y	269.73%
Dividend Est.	-	EV/EBITDA	42.70	Sales past 3/5Y	9.14% 7.06%	Gross Margin	61.07%	Volatility	4.10% 3.36%	Perf 5Y	123.45%
Dividend TTM	-	EV/Sales	5.50	EPS Y/Y TTM	-1067.00%	Oper. Margin	7.44%	ATR (14)	1.50	Perf 10Y	316.93%
Dividend Ex-Date	Dec 09, 2015	Quick Ratio	2.25	Sales Y/Y TTM	9.81%	Profit Margin	-2.16%	RSI (14)	52.57	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	343.96%	SMA20	-0.68%	Beta	1.59	Target Price	51.71
Payout	-	Debt/Eq	0.60	Sales Q/Q	18.39%	SMA50	5.35%	Rel Volume	0.54	Prev Close	45.12
Employees	1600	LT Debt/Eq	0.58	Earnings	Nov 06 AMC	SMA200	35.60%	Avg Volume	411.82K	Price	45.07
IPO	Feb 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	660.23% 2.67%	Trades		Volume	82,995	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	Ladenburg Thalmann	Buy → Neutral	$38.80
Jun-17-25	Initiated	Canaccord Genuity	Buy	$35
Oct-23-24	Initiated	JMP Securities	Mkt Outperform	$33
Sep-27-22	Reiterated	Lake Street	Buy	$32 → $28
Aug-08-22	Initiated	Lake Street	Buy	$32
Mar-03-22	Initiated	Stifel	Buy	$30

Nov-13-25 12:36AM	5 Must-Read Analyst Questions From Artivion's Q3 Earnings Call (StockStory)
Nov-07-25 09:26AM	AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook (StockStory) -5.54%
12:01AM	Artivion Inc (AORT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-25 06:15PM	Artivion (AORT) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:15PM	Artivion: Q3 Earnings Snapshot (Associated Press Finance)
04:33PM	Loading…
04:33PM	Artivion's (NYSE:AORT) Q3 Sales Top Estimates (StockStory)
04:05PM	Artivion Reports Third Quarter 2025 Financial Results (PR Newswire)
08:00AM	Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial (PR Newswire)
Nov-05-25 08:50AM	Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:19PM	Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-29-25 04:10PM	Artivion to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
08:09AM	Strong Results and Improved Guidance Lifted Artivion (AORT) (Insider Monkey)
Oct-23-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results (PR Newswire)
Oct-15-25 11:33PM	Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way (StockStory)
12:02AM	3 Reasons to Sell AORT and 1 Stock to Buy Instead (StockStory)
08:00AM	Loading…
Oct-13-25 08:00AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
Sep-25-25 08:48AM	Are Options Traders Betting on a Big Move in Artivion Stock? (Zacks)
Sep-05-25 04:10PM	Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
Aug-14-25 01:35AM	5 Must-Read Analyst Questions From Artivion's Q2 Earnings Call (StockStory)
Aug-12-25 10:01AM	1 Safe-and-Steady Stock to Target This Week and 2 We Find Risky (StockStory)
Aug-11-25 09:40AM	AORT Q2 Deep Dive: Product Momentum and Pipeline Advances Drive Upgraded Guidance (StockStory)
Aug-09-25 10:05AM	Artivion price target raised to $45 from $32 at Needham (TipRanks)
Aug-08-25 12:21PM	Why Is Artivion (AORT) Stock Rocketing Higher Today (StockStory) +25.23%
04:51AM	Artivion (NYSE:AORT) Reports Strong Q2, Stock Jumps 13.1% (StockStory)
Aug-07-25 06:05PM	Artivion (AORT) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	Artivion: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Artivion Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 02:51PM	Artivion (AORT) Stock Is Up, What You Need To Know (StockStory)
Aug-05-25 11:03PM	What To Expect From Artivion's (AORT) Q2 Earnings (StockStory)
Jul-31-25 12:02AM	3 Reasons AORT is Risky and 1 Stock to Buy Instead (StockStory)
04:10PM	Loading…
Jul-30-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-29-25 05:20PM	Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results (PR Newswire)
Jul-23-25 12:33AM	3 Healthcare Stocks with Warning Signs (StockStory)
Jul-21-25 12:30PM	[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Jun-26-25 05:50PM	The 5 Most Interesting Analyst Questions From Artivion's Q1 Earnings Call (StockStory)
Jun-03-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
May-28-25 11:33PM	Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
05:51PM	Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-19-25 07:40AM	AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance (StockStory)
May-14-25 04:01PM	Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-05-25 05:45PM	Artivion (AORT) Lags Q1 Earnings Estimates (Zacks) +15.36%
04:05PM	Artivion Reports First Quarter 2025 Financial Results (PR Newswire)
07:00AM	Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-29-25 09:05AM	3 Stocks Under $50 That Concern Us (StockStory)
Apr-21-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results (PR Newswire)
Apr-15-25 05:11AM	Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Apr-10-25 09:10AM	Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength? (Zacks)
Mar-28-25 05:04AM	Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-24-25 12:20PM	Do Options Traders Know Something About Artivion (AORT) Stock We Don't? (Zacks)
Mar-04-25 04:05PM	Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference (PR Newswire)
Feb-27-25 09:35AM	Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround (Zacks)
Feb-26-25 10:01AM	Artivion price target lowered to $32 from $34 at Needham (TipRanks)
Feb-24-25 04:05PM	Artivion Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -8.22%
Feb-10-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Jan-27-25 08:00AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting (PR Newswire)
Jan-20-25 03:23PM	Is Artivion, Inc. (AORT) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 08:00AM	Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis (PR Newswire)
Nov-07-24 04:05PM	Artivion Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-05-24 04:15PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire) +5.56%
Oct-24-24 04:15PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results (PR Newswire)
Oct-10-24 04:10PM	Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
Aug-08-24 04:05PM	Artivion Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-05-24 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-25-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results (PR Newswire)
Jul-03-24 08:00AM	3 Earnings All-Stars With More Room to Run (InvestorPlace)
Jul-01-24 04:05PM	Artivion Amends Agreements with Endospan (PR Newswire)
Jun-18-24 09:28AM	Do You Think Artivion (AORT) Stock Could Soar? (Insider Monkey)
May-08-24 09:15AM	Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-07-24 09:49AM	Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.81%
May-06-24 05:20PM	Artivion (AORT) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:05PM	Artivion Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 08:05AM	Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-22-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results (PR Newswire)
Apr-15-24 09:40AM	Is Artivion (AORT) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-01-24 04:10PM	Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-29-24 09:15AM	Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-28-24 09:40AM	Are Medical Stocks Lagging Artivion (AORT) This Year? (Zacks)
Mar-12-24 09:40AM	Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-06-24 04:10PM	Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (PR Newswire)
Feb-22-24 09:40AM	Is Artivion (AORT) Outperforming Other Medical Stocks This Year? (Zacks)
09:15AM	Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-21-24 09:55AM	Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet (Zacks)
Feb-16-24 10:39AM	Artivion, Inc. (NYSE:AORT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 04:05PM	Artivion Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-01-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-29-24 08:25AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting (PR Newswire)
Jan-18-24 04:05PM	Artivion Obtains $350 Million in Senior Secured Credit Facilities (PR Newswire)
Dec-06-23 04:15PM	Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer (PR Newswire)
Nov-09-23 08:25AM	Artivion Announces Completion of Enrollment in PERSEVERE Trial (PR Newswire)
Nov-08-23 04:05PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-02-23 04:05PM	Artivion Reports Third Quarter 2023 Financial Results (PR Newswire) +9.88%
Oct-19-23 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results (PR Newswire)
Oct-05-23 04:15PM	Artivion Announces Presentation of Real World Data from Post Market Study of On-X Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin (PR Newswire) +7.71%
04:05PM	Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting (PR Newswire)
Sep-26-23 08:25AM	Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference (PR Newswire)
Sep-14-23 08:05AM	Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase (PR Newswire)
Aug-31-23 09:55AM	Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade (Zacks)
Aug-10-23 09:55AM	Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect? (Zacks)
Aug-03-23 04:05PM	Artivion Reports Second Quarter 2023 Financial Results (PR Newswire)

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis John E	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:36 PM
Horton Amy	Officer	Nov 17 '25	Proposed Sale	45.73	6,000	274,382		Nov 17 12:23 PM
Holloway Jean F	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:04 PM
Holloway Jean F	Officer	Nov 14 '25	Proposed Sale	45.00	6,393	287,685		Nov 14 02:51 PM
Horton Amy	VP, Chief Accounting Officer	Nov 13 '25	Sale	45.86	3,482	159,678	141,380	Nov 14 02:28 PM
Davis John E	Chief Commercial Officer	Nov 13 '25	Sale	45.86	6,563	300,966	198,842	Nov 14 12:10 PM
Mackin James P	President & CEO	Nov 13 '25	Sale	45.86	34,210	1,568,802	800,993	Nov 14 12:09 PM
Holloway Jean F	SVP, General Counsel	Nov 13 '25	Sale	45.86	5,761	264,188	163,408	Nov 14 12:08 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 13 '25	Sale	45.86	4,993	228,969	56,641	Nov 14 12:07 PM
Davis John E	Officer	Nov 14 '25	Proposed Sale	44.67	6,393	285,575		Nov 14 10:35 AM
Horton Amy	Officer	Nov 13 '25	Proposed Sale	45.86	3,482	159,679		Nov 13 04:39 PM
Holloway Jean F	Officer	Nov 13 '25	Proposed Sale	45.86	5,761	264,190		Nov 13 04:25 PM
Mackin James P	Officer	Nov 13 '25	Proposed Sale	45.86	34,210	1,568,812		Nov 13 04:19 PM
Stanton Marshall S.	Officer	Nov 13 '25	Proposed Sale	45.86	4,993	228,970		Nov 13 04:16 PM
Davis John E	Officer	Nov 13 '25	Proposed Sale	45.86	6,563	300,968		Nov 13 04:09 PM
Holloway Jean F	SVP, General Counsel	Nov 11 '25	Option Exercise	11.03	10,000	110,300	179,169	Nov 12 08:12 PM
Holloway Jean F	SVP, General Counsel	Nov 11 '25	Sale	46.18	10,000	461,800	169,169	Nov 12 08:12 PM
Holloway Jean F	SVP, General Counsel	Nov 10 '25	Sale	44.62	2,960	132,072	169,169	Nov 12 08:12 PM
Mackin James P	President & CEO	Nov 10 '25	Sale	44.62	17,580	784,402	835,203	Nov 12 08:08 PM
Davis John E	Chief Commercial Officer	Nov 10 '25	Sale	44.62	3,373	150,500	205,405	Nov 12 08:07 PM
Horton Amy	VP, Chief Accounting Officer	Nov 10 '25	Sale	44.62	1,789	79,823	144,862	Nov 12 08:06 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 10 '25	Sale	44.62	2,566	114,492	61,634	Nov 12 08:05 PM
Stanton Marshall S.	Officer	Nov 11 '25	Proposed Sale	44.62	2,566	114,492		Nov 12 09:25 AM
Mackin James P	Officer	Nov 10 '25	Proposed Sale	44.62	17,580	784,400		Nov 12 08:31 AM
Holloway Jean F	Officer	Nov 11 '25	Proposed Sale	46.18	10,000	461,800		Nov 12 08:30 AM
Holloway Jean F	Officer	Nov 11 '25	Proposed Sale	44.62	2,960	132,072		Nov 12 08:26 AM
Horton Amy	Officer	Nov 10 '25	Proposed Sale	44.62	1,789	79,823		Nov 12 08:20 AM
Davis John E	Officer	Nov 10 '25	Proposed Sale	44.62	3,373	150,500		Nov 12 08:15 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Aug 27 '25	Option Exercise	11.03	18,200	200,746	82,400	Aug 28 06:08 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Aug 27 '25	Sale	44.02	18,200	801,219	64,200	Aug 28 06:08 PM
MARSHALL STANTON	Officer	Aug 27 '25	Proposed Sale	44.02	18,200	801,211		Aug 27 05:39 PM
Holloway Jean F	SVP, General Counsel	Aug 25 '25	Option Exercise	11.03	10,000	110,300	182,129	Aug 26 10:39 AM
Holloway Jean F	SVP, General Counsel	Aug 25 '25	Sale	44.37	10,000	443,700	172,129	Aug 26 10:39 AM
JEAN F HOLLOWAY	Officer	Aug 25 '25	Proposed Sale	44.37	10,000	443,700		Aug 25 09:32 PM
Mackin James P	President & CEO	Aug 15 '25	Sale	42.32	12,500	528,988	852,783	Aug 19 11:28 AM
Mackin James P	Officer	Aug 15 '25	Proposed Sale	42.32	12,500	528,991		Aug 15 02:43 PM
Holloway Jean F	SVP, General Counsel	Aug 12 '25	Option Exercise	26.24	16,975	445,424	195,485	Aug 14 09:58 AM
Holloway Jean F	SVP, General Counsel	Aug 12 '25	Sale	43.01	23,356	1,004,610	172,129	Aug 14 09:58 AM
Davis John E	Chief Commercial Officer	Aug 12 '25	Option Exercise	26.24	10,802	283,444	219,580	Aug 14 09:56 AM
Davis John E	Chief Commercial Officer	Aug 12 '25	Sale	43.67	10,802	471,756	208,778	Aug 14 09:56 AM
JOHN E DAVIS	Officer	Aug 12 '25	Proposed Sale	43.67	10,802	471,753		Aug 12 05:58 PM
JEAN F HOLLOWAY	Officer	Aug 12 '25	Proposed Sale	43.01	23,356	1,004,606		Aug 12 05:19 PM
Horton Amy	VP, Chief Accounting Officer	Aug 08 '25	Option Exercise	29.62	7,992	236,723	154,643	Aug 11 04:37 PM
Horton Amy	VP, Chief Accounting Officer	Aug 08 '25	Sale	38.49	7,992	307,612	146,651	Aug 11 04:37 PM
AMY HORTON	Officer	Aug 08 '25	Proposed Sale	38.49	7,992	307,612		Aug 08 04:07 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Jun 17 '25	Sale	29.50	15,000	442,500	64,200	Jun 18 11:48 AM
MARSHALL STANTON	Officer	Jun 17 '25	Proposed Sale	29.50	15,000	442,500		Jun 17 04:02 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Jun 13 '25	Sale	28.44	26,132	743,131	79,200	Jun 16 08:22 PM
MARSHALL STANTON	Officer	Jun 13 '25	Proposed Sale	28.44	26,132	743,130		Jun 13 04:38 PM
Holloway Jean F	SVP, General Counsel	May 27 '25	Sale	29.00	8,748	253,692	178,510	May 27 05:29 PM
JEAN F HOLLOWAY	Officer	May 27 '25	Proposed Sale	29.00	8,748	253,692		May 27 04:21 PM
SEMEDO ANTHONY B.	Director	May 23 '25	Sale	28.47	2,600	74,027	33,059	May 27 11:38 AM
Anthony Semedo	Director	May 23 '25	Proposed Sale	28.00	2,600	72,800		May 23 01:11 PM
Holloway Jean F	Officer	May 21 '25	Proposed Sale	29.00	9,926	287,854		May 21 04:12 PM
Holloway Jean F	Officer	May 21 '25	Proposed Sale	29.00	9,926	287,854		May 21 02:51 PM
Holloway Jean F	SVP, General Counsel	May 21 '25	Sale	29.00	9,926	287,854	187,258	May 21 02:43 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	May 09 '25	Sale	29.13	10,548	307,265	105,332	May 12 02:31 PM
Stanton Marshall S.	Officer	May 09 '25	Proposed Sale	23.73	10,548	250,304		May 09 05:39 PM
Holloway Jean F	SVP, General Counsel	Mar 11 '25	Option Exercise	21.55	19,092	411,433	215,204	Mar 12 03:41 PM
Holloway Jean F	SVP, General Counsel	Mar 11 '25	Sale	23.61	18,020	425,510	197,184	Mar 12 03:41 PM
Davis John E	Chief Commercial Officer	Mar 11 '25	Option Exercise	21.55	15,910	342,860	223,878	Mar 12 03:32 PM
Davis John E	Chief Commercial Officer	Mar 11 '25	Sale	23.61	15,100	356,549	208,778	Mar 12 03:32 PM
JOHN E DAVIS	Officer	Mar 11 '25	Proposed Sale	23.61	15,100	356,549		Mar 11 04:54 PM
JEAN F HOLLOWAY	Officer	Mar 11 '25	Proposed Sale	23.61	18,020	425,510		Mar 11 04:48 PM
Mackin James P	President & CEO	Mar 06 '25	Option Exercise	21.55	75,615	1,629,503	935,983	Mar 10 05:18 PM
Mackin James P	President & CEO	Mar 06 '25	Sale	24.77	88,439	2,190,848	860,368	Mar 10 05:18 PM
Horton Amy	VP, Chief Accounting Officer	Mar 06 '25	Sale	24.80	1,048	25,995	146,651	Mar 10 05:11 PM
Berry Lance A	Executive VP, CFO	Mar 06 '25	Sale	24.80	4,909	121,764	153,431	Mar 10 05:08 PM
Davis John E	Chief Commercial Officer	Mar 06 '25	Sale	24.80	2,618	64,939	207,968	Mar 10 05:06 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Mar 06 '25	Sale	24.80	1,603	39,761	115,880	Mar 10 05:03 PM
Holloway Jean F	SVP, General Counsel	Mar 06 '25	Sale	24.80	2,124	52,685	196,112	Mar 10 05:00 PM
JAMES P MACKIN	Officer	Mar 06 '25	Proposed Sale	24.76	70,700	1,750,843		Mar 06 04:54 PM
Holloway Jean F	SVP, General Counsel	Mar 05 '25	Sale	25.29	472	11,935	172,743	Mar 06 08:53 AM
Holloway Jean F	Officer	Mar 05 '25	Proposed Sale	25.29	472	11,935		Mar 05 05:46 PM
SEMEDO ANTHONY B.	Director	Mar 05 '25	Buy	25.33	1,500	37,990	35,659	Mar 05 04:01 PM
SEMEDO ANTHONY B.	Director	Mar 05 '25	Buy	25.25	600	15,150	600	Mar 05 04:01 PM
Horton Amy	VP, Chief Accounting Officer	Feb 24 '25	Sale	27.31	3,323	90,738	131,141	Feb 26 03:33 PM
Mackin James P	President & CEO	Feb 24 '25	Sale	27.31	42,156	1,151,112	663,882	Feb 26 02:00 PM
Holloway Jean F	SVP, General Counsel	Feb 24 '25	Sale	27.31	5,335	145,678	149,799	Feb 26 01:57 PM
Davis John E	Chief Commercial Officer	Feb 24 '25	Sale	27.31	6,457	176,315	160,631	Feb 26 01:54 PM
Berry Lance A	Executive VP, CFO	Feb 24 '25	Sale	27.31	3,259	88,990	75,805	Feb 26 01:50 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 24 '25	Sale	27.31	4,687	127,983	79,845	Feb 26 01:46 PM
Holloway Jean F	Officer	Dec 12 '24	Proposed Sale	30.25	4,011	121,333		Dec 12 05:04 PM
Holloway Jean F	SVP, General Counsel	Dec 11 '24	Sale	30.12	8,070	243,109	153,862	Dec 12 04:11 PM
Holloway Jean F	Officer	Dec 11 '24	Proposed Sale	30.12	8,070	243,109		Dec 11 04:59 PM
Horton Amy	VP, Chief Accounting Officer	Dec 06 '24	Sale	29.66	4,329	128,398	135,660	Dec 09 03:34 PM
GREEN ANDREW M	VP Regulatory	Dec 04 '24	Sale	30.00	7,618	228,540	33,503	Dec 04 04:11 PM
ANDREW GREEN	Officer	Dec 04 '24	Proposed Sale	30.00	7,618	228,540		Dec 04 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AORT

Artivion Inc

Upgrade your FINVIZ experience